The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Aduro Biotech
Patents, Royalties, Other Intellectual Property - Stanford University
A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM).
 
Evan W. Alley
No Relationships to Disclose
 
Tawee Tanvetyanon
No Relationships to Disclose
 
Thierry Marie Jahan
Research Funding - Acerta Pharma (Inst); Aduro Biotech (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Epizyme (Inst); Kadmon (Inst); Lilly (Inst); Polaris (Inst)
 
Leena Gandhi
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Consulting or Advisory Role - AstraZeneca; Celldex; Ignyta; Lilly; Merck; Roche/Genentech; Syndax
 
Tobias Peikert
Patents, Royalties, Other Intellectual Property - CANARY (Imbio)
 
James Stevenson
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
 
Katia Schlienger
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Weiqun Liu
No Relationships to Disclose
 
Nitya Nair
No Relationships to Disclose
 
Somayeh Honarmand
Employment - Aduro Biotech; Merck (I)
Stock and Other Ownership Interests - Aduro Biotech; Merck (I)
 
Hedy L. Kindler
Consulting or Advisory Role - Aduro Biotech; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; ERYTECH Pharma; Five Prime Therapeutics; GlaxoSmithKline; ipsen; MedImmune; Merck; Paradox Therapeutics
Research Funding - Aduro Biotech; AstraZeneca; Bayer; Bristol-Myers Squibb; Deciphera; GlaxoSmithKline; Lilly; MedImmune; Merck; Polaris; Verastem